Condition
Mite Allergy
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 4 (1)
Trial Status
Completed2
Terminated1
Enrolling By Invitation1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07427576CompletedPrimary
Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte
NCT04915352Phase 4TerminatedPrimary
Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis
NCT05525650Phase 1Enrolling By InvitationPrimary
Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients
NCT01479205CompletedPrimary
Induction of Allergen Specific Bronchial Immunotolerance After Specific Immunotherapy
Showing all 4 trials